insitro hires a chief medical officer as its first liver-disease drugs head for trials in early 2027

insitro/ML-driven target discovery

insitro named Hideo Makimura chief medical officer to lead its move to human trials. It says programs aimed at genetic drivers of liver fat and scarring will enter the clinic in early 2027, out of nine first-in-class programs that also include an ALS therapy.